Ultromics
Born at the University of Oxford, Ultromics provides autonomous echocardiography analysis through its AI solutions, empowering physicians to make fast, accurate decisions when diagnosing cardiovascular disease. EchoGo Heart Failure is a novel AI device built to indicate heart failure with preserved ejection fraction (HFpEF) by looking only at the apical four-chamber (A4C) echocardiography view. The FDA awarded breakthrough status and cleared the technology for use in 2022. This technology saves clinicians time and allows them to make diagnostic decisions confidently — streamlining care, increasing productivity, and improving patient outcomes.Select partners: Mayo Clinic, MedStar Health, Cleveland Clinic, NHS, OHSU, University of Oxford, Janssen, NCIMI, Cytokinetics, Imbria Pharmaceuticals, Laurel Bridge, Caption Health.
Founded 2017
Employees 100+
Primary contact
4630 Kingsgate, Cascade Way
Oxford Business Park South
OX4 2SU Oxford
United Kingdom
4630 Kingsgate, Cascade Way
Oxford Business Park South
OX4 2SU Oxford
United Kingdom
Funding 💰
Total $58.8M
Select investors Blue Venture Fund, Oxford Science Enterprises, Nina Capital, GV, Optum Ventures, Future Planet Capital, Woodford Investment Management, GT Healthcare Capital Partners
Key people 🧑🤝🧑
- Dr. Ross Upton - Co-founder & CEO
- Prof. Paul Leeson - Co-founder & Chief Medical Officer
- John Russell - Chairman
- Amir Hasan - COO
- Gary Woodward - CTO
- Nancy Spagou - Chief Experience Officer
- Jaco Jacobs - Chief Regulatory and Compliance Officer
Highlights ⭐
- Solving a problem: Cardiovascular disease is the leading cause of mortality in the world, with an estimated 17.9 million deaths each year or 32% of all global deaths. 🔗
- It works: A study published in December 2021 has found that Ultromics' EchoGo platform significantly improved the accuracy and confidence in coronary artery disease (CAD) detection. 🔗
- Top advisory team: Ultromics' scientific advisory board includes world-leading experts like Dr. Patricia A Pellikka from Mayo Clinic, Dr. Federico Asch from MedStar, Dr. Harald Becher from Heart and Stroke Foundation Chair for Cardiovascular Research, Dr. Sanjiv Kaul from Knight Cardiovascular Institute, and Dr. Partho Sengupta from Rutgers Robert Wood Johnson Medical School & University Hospital. 🔗
- Cleared by the FDA: In April 2023, Ultromics was granted FDA Breakthrough Device Designation for its AI-enhanced platform (EchoGo Amyloidosis) for detecting cardiac amyloidosis using only a single commonly acquired ultrasound view of the heart. 🔗
- Media love: Ultromics has been featured in a number of publications, including The Wall Street Journal, Forbes, BBC, The Economist, The Telegraph, and more.
Video ▶️
Awards & Recognitions 🏆
Quotes 💬
“
EchoGo was able to predict patient mortality in the COVID population, when manual analysis could not. The platform could minimize variability between operators; this lower variability of measurements led to a higher predictive value.
— Dr. Federico Miguel Asch, Director of the Echocardiography Core Lab at MedStar Health Research Institute
“
We are pleased to collaborate with Ultromics to help increase the diagnostic accuracy of detection of cardiovascular diseases with echocardiography.
— Dr. Patricia Pellikka, Vice Chair of Department of Cardiovascular Medicine at Mayo Clinic
“
Cardiovascular disease is the leading cause of morbidity and mortality in the United States, and Ultromics offers groundbreaking AI solutions for more accurate diagnosis. We are excited to partner with Dr. Ross Upton and the Ultromics' team, as they promote improved patient outcomes.
— Dr. Emir Sandhu, Managing Director at the Blue Venture Fund 🔗
“
Ultromics' software significantly improves the ability of clinicians to leverage low-cost ultrasound imaging to address cardiovascular disease, one of the greatest healthcare burdens of our generation. We are thrilled to be supporting the Ultromics team in their mission to improve patient lives through AI enabled cardiovascular imaging solutions.
— Dr. Vijay Barathan, Optum Ventures 🔗
“
Ultromics presents a unique application of artificial intelligence in medical diagnostics in that it is trained on an image of moving anatomy. Most importantly, we were immediately impressed by the company's strong health economics argument coupled with improved clinical outcomes. We are delighted to invest in Ultromics at this important stage in the company's growth and look forward to working together to shape the future of imaging diagnostic solutions in cardiology.
— Marta-Gaia Zanchi of Nina Capital 🔗
Last update: April 27, 2023
Disclaimer: We can not guarantee that the information on this page is 100% correct. more